The therapeutic potential of VEGF inhibition in diabetic microvascular complications

American Journal of Cardiovascular Drugs

Volumn 7, Issue 6, 2007, Pages 393-398

  Tremolada, Gemma ^a   Lattanzio, Rosangela ^a   Mazzolari, Gabriella ^a   Zerbini, Gianpaolo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; AGN 211745; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BEVASIRANIB; MIDOSTAURIN; PEGAPTANIB; PROTEIN TYROSINE KINASE INHIBITOR; RANIBIZUMAB; RUBOXISTAURIN; TUMSTATIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VERTEPORFIN;

ANGIOGENESIS; CATARACT; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG INHIBITION; DRUG POTENTIATION; DRUG SCREENING; ENDOPHTHALMITIS; EVIDENCE BASED MEDICINE; GENETIC TRANSCRIPTION; HUMAN; HYPERTENSION; INTRAOCULAR PRESSURE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STIMULATION; THROMBOEMBOLISM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 37149005811     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200707060-00002     Document Type: Review

References (76)

1. Aiello LP, Wong JS. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int 2000; 77: S113-9
2. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006; 28: 1779-802
3. Zhu X, Wu S, Dahut WL, et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007; 49: 186-93
4. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76
5. Vincenti V, Cassano C, Rocchi M, et al. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 1996; 93: 1493-5
6. Li X, Eriksson U. Novel VEGF family members: VEGF-B, VEGF-C and VEGF-D. Int J Biochem Cell Biol 2001; 33: 421-6
7. Shibuya M. Vascular endothelial growth factor receptor-2: its unique signalling and specific ligand, VEGF-E. Cancer Sci 2003; 94: 751-6
8. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1 deficient mice. Nature 1995; 376: 62-6
9. Fong GH, Rossant J, Gertsenstein M, et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376: 66-70
10. Dumont DJ, Jussila L, Taipale J, et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 1998; 282: 946-9
11. Mura M, dos Santos CC, Stewart D, et al. Vascular endothelial growth factor and related molecules in acute lung injury. J Appl Physiol 2004; 97: 1605-17
12. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999; 77: 527-43
13. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001; 114: 853-65
14. Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptors. Faseb J 1999; 13: 9-22
15. Sondell M, Sundler F, Kanje M. Vascular endothelial growth factor is a neurotrophic factor which stimulates axonal out-growth through the flk-1 receptor. Eur J Neurosci 2000; 12: 4243-54
16. Storkebaum E, Lambrechts D, Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 2004; 26: 943-54
17. Lambrechts D, Storkebaum E, Morimoto M, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003; 34: 383-94
18. Kempen JH, O'Colmain BJ, Leske MC, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004; 122: 552-63
19. Klein R, Klein BE, Moss SE. The Winsconsin epidemiology study of diabetic retinopathy: a review. Diabetes Metab Rev 1989; 5: 559-70
20. Diabetic retinopathy study group. Preliminary report on effects of photocoagulation theraphy. Am J Ophthalmol 1976; 81: 383-96
21. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy: ETDRS report number 9. Ophthalmology 1991; 98: 766-85
22. Shimura M, Yasuda K, Nakazawa T, et al. Quantifying alterations of macular thickness before and after panretinal photocoaculation in patients with severe diabetic retinopathy and good vision. Ophthalmology 2003; 110: 2386-94
23. Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005; 11: 2279-99
24. Stitt AW, Simpson DA, Boocock C, et al. Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra-ocular tumours. J Pathol 1998; 186: 306-12
25. Boulton M, Foreman D, Williams G, et al. VEGF localisation in diabetic retinopathy. Br J Ophthalmol 1998; 82: 561-8
26. Witmer AN, Blaauwgeers HG, Weich HA, et al. Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey. Invest Ophthalmol Vis Sci 2002; 43: 849-57
27. Sheetz MJ, King LK. Molecular understanding of hyperglicemia's adverse effects for diabetic complications. JAMA 2002; 288: 2579-88
28. Mill JW, Adamis AP, Aiello LP. Vascular endothelium growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev 1997; 13: 37-50
29. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelium growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-7
30. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelium growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-9
31. Funatsu H, Yamashita H, Nakamura S, et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelium growth factor are related to diabetic macular edema. Ophthalmology 2006; 113: 294-301
32. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 445-50
33. Shen J, Samul R, Silva RL, et al. Suppresion of ocular neovascularitazion with siRNA targeting VEGF receptor 1. Gene Ther 2006; 13: 225-34
34. Macugen Diabetic Study group. A phase II randomised double-masked trial of pegabtanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmolgy 2005; 112: 1747-57
35. Adamis AP, Altaweel M, Bressler NM, et al., for the Macugen Diabetic Retinopathy Study Group. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006; 113: 23-8
36. Chun DW, Heier JS, Topping TM, et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 2006; 113: 1706-12
37. Avery RL. Regression of retinal and iris neovascolarization after intravitreal bevacizumeb (Avastin) treatment. Retina 2006; 26: 356-7
38. Spaide RF, Fischer YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemmorage. Retina 2006; 26: 275-8
39. Avery RL, Pearlman J, Pieramici DJ, et al. Intraviteal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113: 363-72
40. Jager RD, Aiello LP, Patel SC, et al. Risk of intravenous injection: a comprehensive review. Retina 2004; 24: 676-98
41. Gragoudas ES, Adamis AP, Cunningham Jr ET, et al. Pegabtanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-16
42. Chong NV, Adewoyin T. Intravitreal injection: balancing the risks. Eye 2007; 21: 313-6
43. Saishin Y, Sayshin Y, takahashi K, et al. VEGF-TRAP (R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of blood-retinal barrier. J Cell Physiol 2003; 195: 241-8
44. Ryan AJ, Wedge SR. ZD647: a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer 2005; 92 Suppl. 1: S6-13
45. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005; 65: 4389-400
46. Hess-Stumpp H, Haberey M, Thierauch KH. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy. Chembiochem 2005; 6: 550-7
47. Rosen LS. VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist 2005; 10: 382-91
48. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelium growth factor-induced retinal permeability is mediate by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor. Diabetes 1997; 46: 1473-80
49. Danis RP, Bingaman DP, Jirousek M, et al. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PCK β inhibition with LY333531. Invest Ophthalmol Vis Sci 1998; 39: 171-9
50. The PCK-DRS Study group. The effect of ruboxistaurin on visual loss in patients with moderately severe to severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C β inhibitor Diabetic Retinopathy Study (PCK-DRS) multicenter randomised clinical trial. Diabetes 2005; 54: 2188-97
51. Aiello LP, Clermont A, Arora V, et al. Inhibition of PCK β by oral administration of ruboxistaurine is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Vis Sci 2006; 47: 86-92
52. Eggers PW. Effect of transplantation on the Medicare endstage renal disease program. N Engl J Med 1988; 318: 223-6
53. USRDS. Annual Data Report 1994. Incidence and causes of treated ESRD. Am J Kidney Dis 1994; 24: S48-56
54. Borch-Johnsen K, Andersen PK, Deckert T. The effect of proteinuria on relative mortality in type I (insulin-dependent) diabetes mellitus. Diabetologia 1985; 28: 290-6
55. Brown LF, Berse B, Tognazzi K, et al. Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int 1992; 42: 1457-61
56. Khamaisi M, Schrijvers BF, De Vriese AS, et al. The emerging role of VEGF in diabetic kidney disease. Nephrol Dial Transplant 2003; 8: 1427-30
57. Simon M, Grone HJ, Johren O, et al. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol 1995; 268: F240-50
58. Simon M, Rocckl W, Hornig C, et al. Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: localisation and [125I]VEGF binding sites. J Am Soc Nephrol 1998; 9: 1032-44
59. Brenchley PE. VEGF/VPF: a modulator of microvascular function with potential roles in glomerular pathophysiology. J Nephrol 1996; 9: 10-7
60. Cooper ME, Vranes D, Youssef S, et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999; 48: 2229-39
61. Tsuchida K, Makita Z, Yamagishi S, et al. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia 1999; 42: 579-88
62. Nyengaard JR, Rasch R. The impact of experimental diabetes mellitus in rats on glomerular capillary number and sizes. Diabetologia 1993; 36: 189-94
63. de Vriese AS, Tilton RG, Elger M, et al. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001; 12: 993-1000
64. Sung SH, Ziyadeh FN, Wang A, et al. Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol 2006; 17: 3093-104
65. Schrijvers BF, Flyvbjerg A, Tilton RG, et al. A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat. Nephrol Dial Transplant 2006; 21: 324-9
66. Yamamoto Y, Maeshima Y, Kitayama H, et al. Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes 2004; 53: 1831-40
67. Schrijvers BF, De Vriese AS, Tilton RG, et al. Inhibition of vascular endothelial growth factor (VEGF) does not affect early renal changes in a rat model of lean type 2 diabetes. Horm Metab Res 2005; 37: 21-5
68. Vinik AI, Mitchell BD, Leichter SB, et al. Epidemiology of the complications of diabetes. In: Leslie RDG, Robbins DC, editors. Diabetes: clinical science in practice. Cambridge: Cambridge University Press, 1994: 221-87
69. Sköld MK. VEGF and VEGF receptor expression after experimental brain contusion in rat. J Neurotrauma 2005; 22: 353-67
70. Mukouyama YS, Gerber HP, Ferrara N, et al. Peripheral nerve-derived VEGF promotes arterial differentiation via neuropilin 1-mediated positive feedback. Development 2005; 132: 941-52
71. Storkebaum E, Lambrechts D, Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioassays 2004; 26: 943-54
72. Schratzberger P, Walter DH, Rittig K, et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest 2001; 107: 1083-92
73. Murakami T, Arai M, Sunada Y, et al. VEGF 164 gene transfer by electroporation improves diabetic sensory neuropathy in mice. J Gene Med 2006; 8: 773-81
74. Schratzberger P, Schratzberger G, Silver M, et al. Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy. Nat Med 2000; 6: 405-13
75. Chattopadhyay M, Krisky D, Wolfe D, et al. HSV-mediated gene transfer of vascular endothelial growth factor to dorsal root ganglia prevents diabetic neuropathy. Gene Ther 2005; 12: 1377-84
76. Price SA, Dent C, Duran-Jimenez B, et al. Gene transfer of an engineered transcription factor promoting expression of VEGF-A protects against experimental diabetic neuropathy. Diabetes 2006; 55: 1847-54